{
  "drug_name": "Meropenem",
  "tradename": "Merrem",
  "usage_and_dosing": {
    "general": [
      "Meropenem is a carbapenem with a broad spectrum of activity against aerobic and anaerobic gram-negative bacilli and gram-positive cocci. Activity includes aerobic gram-negative bacilli that produce extended-spectrum beta-lactamase (ESBL).",
      "Meropenem is FDA-approved for intra-abdominal infections and complicated skin/skin structure infections in adult and pediatric patients, and bacterial meningitis in pediatric patients age ≥3 months.",
      "Activity vs aerobic gram-negatives slightly better than imipenem, whereas activity vs staphylococci and streptococci is slightly less. Anaerobic coverage equivalent to imipenem. B. ovatus, B. distasonis are more resistant to meropenem.",
      "An alternative antibiotic for drug-resistant genotypes.",
      "Other uses (not FDA-approved) include Burkholderia pseudomallei (melioidosis).",
      "Allergy",
      "For allergy considerations, see Carbapenems, Overview",
      "See protocol for desensitization."
    ],
    "adult_dose": {
      "usual_dose": "1-2 gm IV q8h",
      "other_dosing": "Continuous, Extended Infusion Dosing",
      "critically_ill": "In the most critically ill, it may be necessary to increase dose to 2 gm q8h and prolong the infusion time of each dose (Antimicrob Agents Chemother 2015;59:2995).",
      "meningitis_dosing": "up to 2 gm IV q8h. To help overcome low level of CSF penetration, infuse each dose over 4 hrs (Antimicrob Agents Chemother 2016;60:6619)."
    },
    "pediatric_dose": {
      "usual_dose": "60 mg/kg/day (divided q8h)",
      "meningitis_cf": "120 mg/kg/day (divided q8h)",
      "max_day": "6 gm"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "1",
    "half_life_esrd": "10",
    "dose_renal_function_normal": "1 gm IV q8h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 26-50: 1 gm q12h. CrCl 10-25: 0.5 gm q12h. CrCl <10: 0.5 gm q24h",
    "hemodialysis": "0.5 gm q24h (AD on dialysis days)",
    "capd": "0.5 gm q24h",
    "crrt": "CVVH, CVVHD: 0.75-1 gm IV q8h 29",
    "sled": "1 gm q8-12h 30"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "Obesity: See Obesity Dosing Adjustments.",
    "ECMO: See ECMO Drug Dosing Adjustment."
  ],
  "adverse_effects": [
    "GI (nausea, vomiting, diarrhea, C. difficile infection)",
    "Hypersensitivity (rash, urticaria, anaphylaxis)",
    "Local phlebitis",
    "Hematologic: neutropenia, eosinophilia, thrombocytopenia",
    "Increased LFTs",
    "Seizure risk, use for valproic acid overdose: see Carbapenems, Overview"
  ],
  "pregnancy_risk": {
    "fda_risk_category": "Humans: insufficient data to establish risk. Animals: no evidence of toxicity. Considered safe for use in pregnant patients.",
    "lactation": "Probably safe with monitoring, but no data available",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [
      "Bacteroides fragilis",
      "Citrobacter freundii",
      "Citrobacter koseri, diversus",
      "E. coli, extended spectrum beta lactamase producer (ESBL)",
      "Providencia sp.",
      "Pseudomonas aeruginosa",
      "Resistant (ESBL) oxytoca, pneumoniae, variicola"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "49 (1 gm IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "2",
    "volume_of_distribution_vd_l_kg": "0.23-0.35 L/kg",
    "avg_serum_half_life_hr": "1",
    "elimination": "Renal",
    "bile_penetration_percent": "3-300",
    "csf_blood_percent": "21-39 (inflamed meninges)",
    "therapeutic_levels_in_csf": "Possibly 9",
    "auc_ug_hr_ml": "72.5 (1 gm IV, 0-inf)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": ["OAT1", "OAT3"],
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
      {
          "drug": "BCG",
          "effect": "↓ effectiveness of BCG",
          "management": "Monitor"
      },
      {
          "drug": "Probenecid",
          "effect": "↑ meropenem",
          "management": "Monitor"
      },
      {
          "drug": "Valproic acid",
          "effect": "↓ valproic acid",
          "management": "Avoid co-administration"
      }
  ]
}
